Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLCAutologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
/in Breast Cancer, Dendritic Cells, International PublicationsLong-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
/in Dendritic Cells, International Publications, Malignant MelanomaPhase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
/in Dendritic Cells, International Publications, Soft Tissue SarcomaDendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models
/in Breast Cancer, Dendritic Cells, International PublicationsPrognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy
/in Breast Cancer, Dendritic Cells, International PublicationsSafety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
/in Dendritic Cells, International Publications, Malignant MelanomaImmune escape mechanisms and immunotherapy of urothelial bladder cancer
/in Dendritic Cells, International Publications, Urothelial CarcinomaDendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
/in Dendritic Cells, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer